Literature DB >> 33574093

Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer.

Sonia Dagnino1, Barbara Bodinier1, Florence Guida2, Karl Smith-Byrne2, Dusan Petrovic1,3,4, Matthew D Whitaker1, Therese Haugdahl Nøst5, Claudia Agnoli6, Domenico Palli7, Carlotta Sacerdote8, Salvatore Panico9, Rosario Tumino10, Matthias B Schulze11,12, Mikael Johansson13, Pekka Keski-Rahkonen2, Augustin Scalbert2, Paolo Vineis1,14, Mattias Johansson2, Torkjel M Sandanger5, Roel C H Vermeulen1,15, Marc Chadeau-Hyam16,15.   

Abstract

Increasing evidence points to a role for inflammation in lung carcinogenesis. A small number of circulating inflammatory proteins have been identified as showing elevated levels prior to lung cancer diagnosis, indicating the potential for prospective circulating protein concentration as a marker of early carcinogenesis. To identify novel markers of lung cancer risk, we measured a panel of 92 circulating inflammatory proteins in 648 prediagnostic blood samples from two prospective cohorts in Italy and Norway (women only). To preserve the comparability of results and protect against confounding factors, the main statistical analyses were conducted in women from both studies, with replication sought in men (Italian participants). Univariate and penalized regression models revealed for the first time higher blood levels of CDCP1 protein in cases that went on to develop lung cancer compared with controls, irrespective of time to diagnosis, smoking habits, and gender. This association was validated in an additional 450 samples. Associations were stronger for future cases of adenocarcinoma where CDCP1 showed better explanatory performance. Integrative analyses combining gene expression and protein levels of CDCP1 measured in the same individuals suggested a link between CDCP1 and the expression of transcripts of LRRN3 and SEM1. Enrichment analyses indicated a potential role for CDCP1 in pathways related to cell adhesion and mobility, such as the WNT/β-catenin pathway. Overall, this study identifies lung cancer-related dysregulation of CDCP1 expression years before diagnosis. SIGNIFICANCE: Prospective proteomics analyses reveal an association between increased levels of circulating CDCP1 and lung carcinogenesis irrespective of smoking and years before diagnosis, and integrating gene expression indicates potential underlying mechanisms.See related commentary by Itzstein et al., p. 3441. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33574093      PMCID: PMC7611235          DOI: 10.1158/0008-5472.CAN-20-3454

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  45 in total

Review 1.  Wnt signaling in cancer.

Authors:  Paul Polakis
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

2.  Differential Serum Cytokine Levels and Risk of Lung Cancer Between African and European Americans.

Authors:  Sharon R Pine; Leah E Mechanic; Lindsey Enewold; Elise D Bowman; Bríd M Ryan; Michele L Cote; Angela S Wenzlaff; Christopher A Loffredo; Susan Olivo-Marston; Anil Chaturvedi; Neil E Caporaso; Ann G Schwartz; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-28       Impact factor: 4.254

3.  Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis.

Authors:  Takamasa Uekita; Satoko Fujii; Yuri Miyazawa; Reika Iwakawa; Mako Narisawa-Saito; Katsuhiko Nakashima; Koji Tsuta; Hitoshi Tsuda; Tohru Kiyono; Jun Yokota; Ryuichi Sakai
Journal:  Mol Cancer Res       Date:  2014-06-17       Impact factor: 5.852

4.  Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.

Authors:  Meredith S Shiels; Hormuzd A Katki; Allan Hildesheim; Ruth M Pfeiffer; Eric A Engels; Marcus Williams; Troy J Kemp; Neil E Caporaso; Ligia A Pinto; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2015-07-28       Impact factor: 13.506

Review 5.  Inflammation in the development of lung cancer: epidemiological evidence.

Authors:  Eric A Engels
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

6.  Transcriptional regulation of livin by beta-catenin/TCF signaling in human lung cancer cell lines.

Authors:  Dong Yuan; Liqun Liu; Dayong Gu
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

7.  Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.

Authors:  Florence Guida; Nan Sun; Leonidas E Bantis; David C Muller; Peng Li; Ayumu Taguchi; Dilsher Dhillon; Deepali L Kundnani; Nikul J Patel; Qingxiang Yan; Graham Byrnes; Karel G M Moons; Anne Tjønneland; Salvatore Panico; Claudia Agnoli; Paolo Vineis; Domenico Palli; Bas Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Jose M Huerta; Miren Dorronsoro; Miguel Rodriguez Barranco; Eva Ardanaz; Ruth C Travis; Karl Smith Byrne; Heiner Boeing; Annika Steffen; Rudolf Kaaks; Anika Hüsing; Antonia Trichopoulou; Pagona Lagiou; Carlo La Vecchia; Gianluca Severi; Marie-Christine Boutron-Ruault; Torkjel M Sandanger; Elisabete Weiderpass; Therese H Nøst; Kostas Tsilidis; Elio Riboli; Kjell Grankvist; Mikael Johansson; Gary E Goodman; Ziding Feng; Paul Brennan; Mattias Johansson; Samir M Hanash
Journal:  JAMA Oncol       Date:  2018-10-11       Impact factor: 31.777

8.  ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.

Authors:  Kuo-Liang Chiu; Yu-Sen Lin; Ting-Ting Kuo; Chia-Chien Lo; Yu-Kai Huang; Hsien-Fang Chang; Eric Y Chuang; Ching-Chan Lin; Wei-Chung Cheng; Yen-Nien Liu; Liang-Chuan Lai; Yuh-Pyng Sher
Journal:  Oncotarget       Date:  2017-07-18

Review 9.  Quantitative proteomics in lung cancer.

Authors:  Chantal Hoi Yin Cheung; Hsueh-Fen Juan
Journal:  J Biomed Sci       Date:  2017-06-14       Impact factor: 8.410

10.  A molecular epidemiology project on diet and cancer: the EPIC-Italy Prospective Study. Design and baseline characteristics of participants.

Authors:  Domenico Palli; Franco Berrino; Paolo Vineis; Rosario Tumino; Salvatore Panico; Giovanna Masala; Calogero Saieva; Simonetta Salvini; Marco Ceroti; Valeria Pala; Sabina Sieri; Graziella Frasca; Maria Concetta Giurdanella; Carlotta Sacerdote; Laura Fiorini; Egidio Celentano; Rocco Galasso; Adriano Decarli; Vittorio Krogh
Journal:  Tumori       Date:  2003 Nov-Dec
View more
  4 in total

1.  Considerations of biomarker application for cancer continuum in the era of precision medicine.

Authors:  Rayjean J Hung; Elham Khodayari Moez; Shana J Kim; Sanjeev Budhathoki; Jennifer D Brooks
Journal:  Curr Epidemiol Rep       Date:  2022-07-09

2.  AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.

Authors:  Yuichi Murakami; Daiki Kusakabe; Kosuke Watari; Akihiko Kawahara; Koichi Azuma; Jun Akiba; Masahiko Taniguchi; Michihiko Kuwano; Mayumi Ono
Journal:  Sci Rep       Date:  2022-05-28       Impact factor: 4.996

3.  Overexpression of CDCP1 is Associated with Poor Prognosis and Enhanced Immune Checkpoints Expressions in Breast Cancer.

Authors:  Jinlu Zhao; Jie Mei; Fengxu Wang; Xinyuan Zhao; Yi Ren; Xingyu Zhao; Wang Li; Erli Gao
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

4.  CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer.

Authors:  Yunha Nam; Chang-Min Choi; Young Soo Park; HyunA Jung; Hee Sang Hwang; Jae Cheol Lee; Jung Wook Lee; Jung Eun Lee; Jung Hee Kang; Byung Hun Jung; Wonjun Ji
Journal:  J Clin Med       Date:  2022-01-11       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.